Ganapathy-Kanniappan et al.'s research found that injection of GAPDH antagonists into mouse liver cancer models can induce apoptosis of liver cancer cells and block the progression of Hep3B tumors, which may be used as a potential target therapy for HCC [25]. This evidence concerns the gene GAPDH and liver cancer.